Alpha 2.0
Login Register
» Articles » PMID: 2425731

PPi Analogs As Inhibitors of Human T-lymphotropic Virus Type III Reverse Transcriptase

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1986 May 1
PMID 2425731
Citations 22
Authors
L Vrang
B Oberg
Affiliations
Soon will be listed here.
Abstract

Twenty-six PPi analogs were tested for inhibitory effects on human T-lymphotropic virus type III reverse transcriptase. The structural requirements for inhibition and mechanism of action of the most active inhibitors have been investigated. Foscarnet (phosphonoformic acid) was the most potent inhibitor of human T-lymphotropic virus type III reverse transcriptase with 50% inhibition at 0.5 microM. The mechanism was a noncompetitive type of inhibition of a (riboadenylic acid)n . (deoxythymidylic acid)12-18 [(rA)n(dT)12-18]-directed transcription at varied dTTP concentration. At constant substrate (dTTP) concentration and varied amounts of template, (rA)n(dT)12-18, the inhibitory action of foscarnet was of an uncompetitive type. The same pattern of inhibition was seen when the less active inhibitor carbonyldiphosphonate was studied under identical conditions. The structural requirements for inhibition of human T-lymphotropic virus type III reverse transcriptase by PPi analogs were similar to those shown by other reverse transcriptases.

Citing Articles

Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.

Das K, Balzarini J, Miller M, Maguire A, DeStefano J, Arnold E ACS Chem Biol. 2016; 11(8):2158-64.

PMID: 27192549 PMC: 4992415. DOI: 10.1021/acschembio.6b00187.

Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Meyer P, Matsuura S, Zonarich D, Chopra R, Pendarvis E, Bazmi H J Virol. 2003; 77(11):6127-37.

PMID: 12743270 PMC: 155000. DOI: 10.1128/jvi.77.11.6127-6137.2003.

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J J Virol. 1996; 70(10):7171-81.

PMID: 8794364 PMC: 190770. DOI: 10.1128/JVI.70.10.7171-7181.1996.

Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Sandstrom E, Oberg B Drugs. 1993; 45(5):637-53.

PMID: 7686460 DOI: 10.2165/00003495-199345050-00002.

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Wagstaff A, Bryson H Drugs. 1994; 48(2):199-226.

PMID: 7527325 DOI: 10.2165/00003495-199448020-00007.

References
1.
Sundquist B, Larner E . Phosphonoformate inhibition of visna virus replication. J Virol. 1979; 30(3):847-51. PMC: 353395. DOI: 10.1128/JVI.30.3.847-851.1979. View
2.
Sundquist B, Oberg B . Phosphonoformate inhibits reverse transcriptase. J Gen Virol. 1979; 45(2):273-81. DOI: 10.1099/0022-1317-45-2-273. View
3.
Eriksson B, Larsson A, Helgstrand E, Johansson N, Oberg B . Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta. 1980; 607(1):53-64. DOI: 10.1016/0005-2787(80)90220-8. View
4.
Eriksson B, Stening G, Oberg B . Inhibition of reverse transcriptase activity of avian myeloblastosis virus by pyrophosphate analogues. Antiviral Res. 1982; 2(1-2):81-95. DOI: 10.1016/0166-3542(82)90028-6. View
5.
Popovic M, Sarngadharan M, Read E, Gallo R . Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224(4648):497-500. DOI: 10.1126/science.6200935. View